ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine’s 2024 ...

Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine&CloseCurlyQuote ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine’s 2024 list of ...

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine's 2024 list of ...

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME ...

PainReform previously disclosed initial topline data from its Phase 3 clinical trial in which it reported that it demonstrated statistically significant superiority over placebo in reducing pain ...

A bipartisan Senate Intelligence Committee report released Friday slammed the CIA for its treatment of patients with a ...

Mizuho lowered the firm’s price target on Icon (ICLR) to $260 from $295 and keeps an Outperform rating on the shares in conjunction with ...